Elos Medtech launches Elos Accurate[®] Hybrid Base™ in the U.S.
Elos Medtech is pleased to announce that the company has received FDA 510(k) clearance to market Elos Accurate Hybrid Base on the U.S. dental implant market. Elos Accurate Hybrid Base is a prosthetic product within digital dentistry and is used for single crowns and bridges on dental implants. The product is compatible with several implant platforms from leading dental implant companies and has so far only been sold on the European market. By the clearance of Elos Accurate Hybrid Base, we get a complete offer within our digital product portfolio in the U.S.
The North American market is of significant importance and is estimated to constitute approximately 35% of the total global dental implant market. The segment of milled customized prosthetics is growing compared to the conventional casting technique. Elos Accurate workflow therefore fills a valued position within the evolving needs of openness within digital dentistry. The Elos Accurate Hybrid Base will primarily be marketed to dental laboratories which offer their customers modern and efficient prosthetic solutions within digital dentistry.
Thanks to Elos Medtech’s collaborations and partnerships with many of the leading global companies within software, 3D-models and dental implants, Elos Accurate enables a trustworthy open digital workflow. The open solution provided by Elos Medtech is recognized by a growing number of dental customers worldwide.
“We are looking forward to presenting Elos Accurate as a full product assortment portfolio within the digital workflow at the biggest dental laboratory event, Lab Day Chicago, later this week. The Elos Accurate Hybrid Base fulfills our platform for the growth of own dental products globally. We are excited to launch on the American market during spring together with our distributor Vulcan Custom Dental,” says Søren Olesen, Global Business Director Dental, Elos Medtech.
Elos Medtech is a leading development and production partner for medical devices and components, with a focus on dental and orthopedic implants and instruments. The company operates from facilities in Sweden, Denmark, China and the U.S. The customer base comprises international medical technology companies.
Elos Medtech has more than 550 employees and a turnover of more than SEK 650 million. Elos Medtech has been listed on NASDAQ Stockholm AB since 1989. Elos Medtech’s B share is categorized as a Health Care company on the Small Cap list.
Gothenburg, February 19, 2020
Elos Medtech AB (publ)
For further information, please contact:
Jan Wahlström, President and CEO, +46 70 212 18 89, jan.wahlstrom@elosmedtech.com
Søren Olesen, Global Business Director Dental, +45 40 41 28 82, soren.olesen@elosmedtech.com
For additional information about the Elos Medtech Group, visit www.elosmedtech.com
For additional information about the Elos Dental Solutions, visit www.elosdental.com